#EASL2023 Archives - Page 2 of 2

Dr. Wenshi Wang’s Team: Three Latest Research Findings on Hepatitis D and Hepatitis E Included in Conference Exchange

By Lisa Cui 2024.01.14

Hepatitis D (HDV) is a viral hepatitis caused by hepatitis D virus (HDV) infection, often occurring as a co-infection or superinfection with hepatitis B virus (HBV). Approximately 90% of chronic…

Dr. Minghua Zheng’s Team: AI-Based Digital Pathology Provides New Insights into NASH Fibrosis Reversal Induced by Lifestyle Intervention

By Mourabit Halima 2024.01.14

Non-Alcoholic Steatohepatitis (NASH) is a common cause of chronic liver disease, and the degree of liver fibrosis is an important factor determining its clinical prognosis. Lifestyle intervention is the cornerstone…

Dr. Yong-an Ye ‘s Team: Using Machine Learning-Based Predictive Models to Identify Early Virological Recurrence Risk in Chinese Chronic Hepatitis B Patients After Entecavir Discontinuation

By Lisa Cui 2024.01.14

Currently, most chronic hepatitis B (CHB) patients cannot achieve a cure. While guidelines suggest that some CHB patients can discontinue nucleos(t)ide analogs (NAs) after consolidation therapy, virological recurrence remains common.…

Seven Achievements from Peking University Hepatology Institute Shine at EASL 2023

By Mourabit Halima 2023.12.25

From June 21st to 24th, the annual international liver disease conference, the 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and EASL Congress…